Blog

PALO ALTO, CA. July 5, 2022 /Newswire/ -- Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial biopharmaceutical company focused...

27 Jun

SEC FIlings

Registration of securities, business combinations – Amendment

November 17, 2022
Posted by Jitendra

16 Jun

SEC FIlings

Prospectuses and communications, business combinations

November 17, 2022
Posted by Jitendra

14 Jun

Press Release

Scilex Holding Company, a Sorrento Company, enters into an agreement for an exclusive license with ROMEG Therapeutics, LLC, for the right to commercialize Gloperba®, an FDA-approved prophylactic treatment for painful gout flares in adults, in the US.

June 28, 2022
Posted by Jitendra

Gloperba is an FDA-approved, oral medication for treating painful gout flares in adults.Gout is a painful arthritic disorder affecting an estimated 8.7 million people in the United States1. As gout cases increase...

07 Jun

SEC FIlings